Roche wins final UK okay for discounted Tarceva

LONDON (Reuters) - Roche Holding AG’s lung cancer drug Tarceva has won final approval for use by Britain’s state health service after the Swiss drugmaker agreed to discount the price of the medicine.

The National Institute for Health and Clinical Excellence (NICE) now recommends Tarceva as an alternative to Sanofi-Aventis SA’s Taxotere for people who have already tried one chemotherapy regime without success.

But NICE, which decides which treatments should be funded by the state in England and Wales, said Roche’s drug should only be used if its overall treatment cost did not exceed that of Taxotere.

The new price for a 125-day course of Tarceva treatment is 6,128 pounds ($9,265), compared with a previous typical cost of 6,800 pounds.

NICE had originally recommended against Tarceva, arguing that buying the costly drug, also known as erlotinib, was not a good use of National Health Service (NHS) resources.

Tarceva — which is relatively unusual among cancer treatments in that it is given by mouth rather than injection — is one of a new generation of targeted drugs that attack only cancer cells, making them better tolerated than traditional chemotherapy.

It was licensed and launched in Britain in 2005 but Roche has since been fighting to get it paid for by the NHS.

Roche had already announced in October 2007 that it was cutting the British price of Tarceva as an interim measure.

Tarceva was discovered by OSI Pharmaceuticals Inc and further developed by Roche and Genentech Inc, which sells it in the United States.

(Reporting by Ben Hirschler; editing by Elaine Hardcastle)


Related Posts:

LONDON (Reuters) - Britain’s healthcare cost effectiveness watchdog NICE has rebuffed GlaxoSmithKline’s latest bid to get its drug Tyverb - for women with advanced breast cancer - into the state health system, the company said on Tuesday. Glaxo said as part of the ongoing appeal it had offered to run a 12-week trial in women with

Full Post: UK’s NICE turns down Glaxo Tyverb offer

LONDON (Reuters) - Greek researchers have identified the chemotherapy combinations that appear to help women with advanced breast cancer live longest, they reported Tuesday. Women who took a combination of a taxane-based therapy such as Taxol or paclitaxel, or Sanofi Aventis’s Taxotere, known generically as docetaxel, with other drugs lived a year longer than women who

Full Post: Certain chemotherapy combinations work best

* Avastin meets goal in breast cancer clinical trial * Study shows Avastin can be added to common chemotherapies * Roche stock up 4.1 percent ZURICH (Reuters) - Roche Holding AG, the world’s largest maker of cancer drugs, said on Monday that Avastin met its primary endpoint in a Phase III breast cancer trial. Roche said Avastin, which it

Full Post: Study boosts Roche’s Avastin in breast cancer

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - The lung cancer pill Iressa has shown surprising results for patients with advanced disease where it has been at least as effective as a standard chemotherapy treatment, researchers reported on Thursday. Patients who got the once-a-day pill made by AstraZeneca lived as long as those given the

Full Post: Lung cancer pill may get second chance after tests

LOS ANGELES (Reuters) - A combination of Genentech Inc’s cancer drug Rituxan and chemotherapy reduces by 41 percent the risk of death or cancer progression, compared with chemotherapy alone, for patients with a common form of leukemia, the company said on Saturday. Results from the pivotal- or final-stage trial found that previously untreated patients given the

Full Post: Genentech drug boosts leukemia patient survival

Site Navigation

Most Read